Cigna Corp. likely to acquire Express Scripts for over $50 billion
Category: #world  By Dhananjay Punekar  Date: 2018-03-09
  • share
  • Twitter
  • Google Plus
  • Facebook
  • LinkedIn

Cigna Corp. likely to acquire Express Scripts for over $50 billion

The United States based health insurance firm Cigna Corporation has apparently declared its intention to buy Express Scripts Holding Company. The largest pharmacy benefit firm in the U.S. is likely to be sold out for a valuation of around USD 54 billion in a cash & stock agreement.

As per medical industry experts, this strategic decision is aimed at reducing the rising healthcare expenditure and improving Cigna’s product & service offering across the healthcare sector. For the record, Cigna’s offer includes USD 48.75 in cash and 0.2434 shares of stock of the combined entity for every share of Express Scripts. It amounts to nearly USD 96.03 per share, which displays a premium of about 31% to the closing market price of Express.

Reports cite that the announcement of the purchase deal between Cigna & Express follows right after the USD 69 billion merger of the U.S. based health insurance firm Aetna Inc. with CVS Health Corporation, a U.S. retail pharmacy & healthcare firm. The mergers & acquisition deals taking place across the healthcare sector display a shift toward major consolidation, claim experts. Elaborating further, they say that these transactions between medical magnates will help bring pharmacy & medical claims under one roof and enhance preventative measures across the hospitals.

After the finalization of the agreement, Cigna Inc.’s investors will possess the ownership of nearly 64% of the shares of the joint entity, while the stakeholders of Express Scripts will own the remaining shares. The key officials of Cigna have announced that the firm is likely to fund the cash for the agreement through Express Scripts’ outstanding debts, new debt issuances, and cash on hand.

As per the company sources, it has already received complete debt financing from The Bank of Tokyo-Mitsubishi UFJ Limited and Morgan Stanley Senior Funding. Incidentally, the deal is valued at a total of USD 67 billion, including close to USD 15 billion in Express Scripts' debts.



About Author

Dhananjay Punekar

Email: dhananjay.p@news.marketsizeforecasters.com   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...